IRMD vs. OFIX, EMBC, SIBN, PLSE, OSUR, SKIN, NVRO, TMCI, ANIK, and NPCE
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include Orthofix Medical (OFIX), Embecta (EMBC), SI-BONE (SIBN), Pulse Biosciences (PLSE), OraSure Technologies (OSUR), Beauty Health (SKIN), Nevro (NVRO), Treace Medical Concepts (TMCI), Anika Therapeutics (ANIK), and NeuroPace (NPCE). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.
Orthofix Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Iradimed has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Orthofix Medical received 158 more outperform votes than Iradimed when rated by MarketBeat users. However, 64.69% of users gave Iradimed an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
In the previous week, Iradimed had 11 more articles in the media than Orthofix Medical. MarketBeat recorded 13 mentions for Iradimed and 2 mentions for Orthofix Medical. Orthofix Medical's average media sentiment score of 0.61 beat Iradimed's score of -0.32 indicating that Iradimed is being referred to more favorably in the news media.
Iradimed has a net margin of 26.48% compared to Iradimed's net margin of -20.28%. Orthofix Medical's return on equity of 24.63% beat Iradimed's return on equity.
89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 4.7% of Orthofix Medical shares are owned by insiders. Comparatively, 42.6% of Iradimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Orthofix Medical presently has a consensus price target of $15.50, suggesting a potential upside of 15.16%. Iradimed has a consensus price target of $62.50, suggesting a potential upside of 43.38%. Given Orthofix Medical's stronger consensus rating and higher probable upside, analysts plainly believe Iradimed is more favorable than Orthofix Medical.
Summary
Iradimed beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
